Further studies are needed to explore the combination of PCPE-1 deficiency with a drug treatment targeting inflammation/ steatosis to evaluate the impact on fibrosis and NASH progression. This evidence concerns the gene PCOLCE and metabolic dysfunction-associated steatohepatitis.